Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
When To Switch From Target Date Fund To Age Based Approach: Go. This intro covers when a switch makes sense and what signals to watch for in your plan.
25,368 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
A U.S. military laser downed a drone near the border, later identified as a CBP asset. Lawmakers blast the handling, ...
Himax (HIMX) faces a pivotal year as AR/VR, automotive displays, and smartphone drivers shape demand. This Q1 2026 ea...
A high-net-worth retiree weighs a 30-year TIPS sleeve to secure inflation-adjusted income, balancing long lock-up ris...
As markets rally, Americans save less than the maximum 401(k) contribution. The gap creates lifetime shortfalls that ...
A high-stakes moment at Davos shifted sentiment in crypto markets. Michael Saylor announced a record BTC purchase, wh...
When a magnificent dividend stock drops 8%, it can feel painful. This guide shows how to separate price swings from l...
Berkshire Hathaway’s planned berkshire taylor morrison deal signals a shift toward an integrated housing platform, wi...
AI infrastructure relies on powerful chip makers. Here's Taiwan Semiconductor (TSM) emerges as a core holding, combin...
When a large investor makes a bold move, the spotlight shifts from fundamentals to signals. This article unpacks how ...
Abcellera's Q1 2026 earnings transcript provides key clues about the path to 2026. This guide breaks down revenue dri...
As Orion (OEC) prepares for 2026 earnings season, this guide breaks down the drivers, cash flow dynamics, and risks t...